CN106434928A - 一组用于肺腺癌早期诊断的circRNA标志物及其应用 - Google Patents
一组用于肺腺癌早期诊断的circRNA标志物及其应用 Download PDFInfo
- Publication number
- CN106434928A CN106434928A CN201610876817.4A CN201610876817A CN106434928A CN 106434928 A CN106434928 A CN 106434928A CN 201610876817 A CN201610876817 A CN 201610876817A CN 106434928 A CN106434928 A CN 106434928A
- Authority
- CN
- China
- Prior art keywords
- circrna
- primer
- seq
- lung
- adenocarcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于生物技术领域,一组用于肺腺癌早期诊断的circRNA标志物及其应用。本发明包括circRNA_100323、circRNA_69774、circRNA_403738、circRNA_ 404449四种circRNA。本发明的有益效果在于提供了一组对肺腺癌有诊断价值的新型生物分子标志物。经临床样本病例验证,本组circRNA对早期肺腺癌的诊断具有较高的诊断特异性和敏感度。
Description
技术领域
本发明属于肿瘤基因检测技术领域,涉及一种用于肺腺癌早期诊断的circRNA标志物、相关试剂盒及它们的用途。
背景技术
肺癌是严重危害人类健康的第一大恶性肿瘤,其发病率(120万/年)和死亡率(110万/年)均居全球癌症首位。2014年《中国肿瘤登记年报》显示,在我国肺癌也是发病率和死亡率最高的恶性肿瘤(我国每年新发肺癌患者人数60万以上)。肺癌5年生存率仅约15.6%,主要原因是多数患者在诊断时已属晚期,因此肺癌的早期发现早期诊断至关重要。
环状RNA是一类由特殊的选择性剪切产生的首尾相接的非编码RNA。起初它们被认为是基因组转录的“噪音”,不具有生物学功能。然而,近年来的研究表明circRNA在人体中发挥着巨大的基因调节功能。与线性RNA分子相比,circRNA作为生物分子标志物具有如下优势:(1)circRNA形成特殊的共价闭合环状结构,3’端没有多聚腺苷酸尾,不会被核酸外切酶R所酶切,因此稳定性高,便于样品的保存;(2)circRNA可以通过外泌体而进入血液、组织液及痰液中,便于取样;(3)circRNA长度多在200-400碱基,使用qPCR即可定量检测,可操作性强。目前已经在食管癌、胃癌、肝癌等恶性肿瘤中相继发现了具有早期诊断价值的circRNA,但是在肺癌领域中尚未见相关circRNA的报道。
发明内容
解决的技术问题:本发明的目的在于提供一组用于肺腺癌早期诊断的circRNA标志物及其应用,为肺腺癌的早期诊断提供参考依据。本发明所提供的circRNA生物标志物对于人肺腺癌具有很高的灵敏度和特异性,尤其对人早期肺腺癌具有很好的检测效果,可以作为新型的生物标志物用于肺腺癌的检测。
技术方案:一组用于肺腺癌早期诊断的circRNA标志物,标志物包括:SEQ ID No:1所示的circRNA_100323、SEQ ID No:2所示的circRNA_69774、SEQ ID No:3所示的circRNA_403738、SEQ ID No:4所示的circRNA_404449四种circRNA。
上述肺腺癌为人早期肺腺癌。
上述circRNA标志物的引物组合,所述circRNA引物的组合包括:针对circRNA_100323的特异性引物、针对circRNA_69774的特异性引物、针对circRNA_403738的特异性引物、针对circRNA_404449的特异性引物。
上述circRNA标志物的引物组合,所述针对circRNA_100323的特异性引物包括如SEQ ID No:9所示的上游引物,如SEQ IDNo:10所示的下游引物;所述针对circRNA_69774的特异性引物包括如SEQ ID No:11所示的上游引物,如SEQ ID No:12所示的下游引物;所述针对circRNA_403738的特异性引物包括如SEQ ID No:13所示的上游引物,如SEQ ID No:14所示的下游引物;所述针对circRNA_404449的特异性引物包括如SEQ ID No:15所示的上游引物,如SEQ ID No:16所示的下游引物。
上述circRNA标志物的引物组合,所述circRNA引物的组合还包括:针对SEQ IDNo:5所示的circRNA_104855的特异性引物、针对SEQ ID No:6所示的circRNA_100983的特异性引物、针对SEQ ID No:7所示的circRNA_1011969的特异性引物、针对SEQ ID No:8所示的circRNA_006718的特异性引物。
上述circRNA标志物的引物组合,所述针对circRNA_104855的特异性引物包括:如SEQ ID No:17所示的上游引物和如SEQ IDNo:18所示的下游引物;所述针对circRNA_100983的特异性引物包括:如SEQ ID No:19所示的上游引物和如SEQ IDNo:20所示的下游引物;所述针对circRNA_1011969的特异性引物包括:如SEQ ID No:21所示的上游引物和如SEQ IDNo:22所示的下游引物;所述针对circRNA_006718的特异性引物包括:如SEQ ID No:23所示的上游引物和如SEQ ID No:24所示的下游引物。
上述circRNA标志物的引物组合在制备或筛选人肺腺癌的肿瘤诊断药物中的用途。
一种人肺腺癌的肿瘤诊断试剂盒,包括所述的circRNA标志物的引物组合。
一种检测人肺腺癌的circRNA芯片,所述circRNA芯片包括固相载体以及固定于固相载体上的针对如上所述的circRNA生物标志物的探针。
本发明所提供的人肺腺癌早期诊断用circRNA生物标志物,可用于肺腺癌的早期诊断。其区分早期肺腺癌和配对正常肺组织的AUC可达0.841,显著性高于这4个circRNAs单独诊断早期肺腺癌的AUC(P<0.05),其ROC曲线表明这4个circRNAs诊断早期肺腺癌的灵敏度和特异性分别为83.4%和73.5%,显著性高于单个circRNA用于肺腺癌诊断的灵敏度和特异性(P<0.05)。
有益效果:(1)本方法通过定量PCR对一组circRNA的检测,实现对肺腺癌的早期诊断,肺癌的早期发现和诊断提供参考价值。(2)本方法特异性强、敏感性高、结果稳定等优点,具有广泛的临床应用前景和巨大的商业价值。
附图说明
图1.本发明8个circRNA联合起来区分训练集(n=30)肺腺癌及其配对正常肺组织的ROC曲线图;
图2.本发明优化的4个circRNA联合起来区分训练集(n=30)肺腺癌及其配对正常肺组织的ROC曲线图;
图3.本发明优化的4个circRNA联合起来区分验证集(n=30)肺腺癌及其配对正常肺组织的ROC曲线图。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式。
实施例1
1临床样本收集:
收集东南大学附属中大医院2013-2014年期间存档的早期(IA期)肺腺癌石蜡组织标本及其配对正常肺组织60对。所有病人对参与科学研究均签署知情同意书。
2 circRNA定量PCR实验:
2.1 RNA抽提及定量PCR
利用Trizol从组织中抽提总RNA,用微体积分光光度计对RNA进行定量。
2.2引物
本发明所提供的一组circRNA包括circRNA_100323、circRNA_69774、circRNA_403738、circRNA_404449、circRNA_104855、circRNA_100983、circRNA_1011969、circRNA_006718等8种circRNA。它们均是从早期肺腺癌患者circRNA芯片检测的结果中挑选的,以GAPDH为内参基因(SEQ ID No:27),引物序列如表1所示:
表1定量PCR使用的引物序列
2.3逆转录反应
使用TakaRa PrimeScript RT reagent Kit试剂盒进行逆转录,RNA起始量为1μg,逆转录反应组分的用量如表2所示,反应条件:37℃15min,85℃5sec完成后低温保存备用。
表2逆转录反应体系组成
2.4实时定量PCR反应
实时定量PCR使用TaKaRa公司的SYBR Premix Ex Taq(Tli RnaseH Plus)试剂盒,定量仪器为BioRad公司CFX96型实时PCR仪。反应体系如表3所示,反应条件如表5所示步骤,每个实时定量PCR反应分别做三个重复。
表3实时定量PCR反应体系
反应程序为:95℃2min;95℃30sec,56℃50sec,40个循环。
数据以平均值±标准差的形式表示,使用SPSS 18.0软件对数据进行统计分析。除非有特殊的说明。肺腺癌与其配对正常肺组织中circRNA的表达差异统计使用配对样本t检验的方法,所有P值均为双侧,P<0.05被认为有统计学意义。
2.5 8个circRNA区分肺腺癌及其配对正常肺组织的能力评估
我们利用ROC曲线来评估这8个区分肺腺癌及其配对正常肺组织的能力。单个circRNA用于肺腺癌诊断的AUC为0.53-0.75,灵敏度为54.4%-77.4%,特异性为49.1%-77.5%(表4)。我们将这8个circRNA联合起来用于30对肺腺癌样本的诊断,其AUC值可达到0.854(图1),在选择合适阈值之后,灵敏度和特异性分别为80.1%和83.3%。
表4 8个circRNA在训练集(30对样本)中的表达情况
2.6优选的4个circRNA区分肺腺癌及其配对正常肺组织的能力评估
通过线性逻辑回归分析,我们从8个circRNA中分析优选得到了4个circRNA。我们利用ROC曲线来评估4个在训练集中区分肺腺癌及其配对正常肺组织的能力(所用30对样本与2.5相同)。这4个circRNA结合起来区分早期肺腺癌和配对正常肺组织的AUC可达0.820(图2所示),接近8个circRNA联合检测水平,并显著高于这4个circRNA单独诊断早期肺腺癌的AUC(P<0.05)。在选择合适的阈值之后,ROC曲线表明这4个circRNA诊断早期肺腺癌的灵敏度和特异性分别为83.3%和80.0%,显著高于单个circRNA用于肺腺癌诊断的灵敏度和特异性(P<0.05)。
表5 4个circRNA在验证集(30对样本)中的诊断结果
我们在另外一组30例肺腺癌样本及其配对正常肺组织(验证集)中验证从训练集筛选出的这4个circRNA的检测特性。这4个circRNA在肺腺癌及其配对正常肺组织均中有显著性差异表达(P<0.001)。单个circRNA用于检测肺腺癌的AUC为0.73-0.82,灵敏度为65.6%-79.3%,特异性为67.9%-76.3%(表5)。这4个circRNA联合检测60对肺腺癌样本的AUC可达0.841(图3),在选择合适的阈值之后,ROC曲线表明其灵敏度为83.4%,特异性为73.5%,均显著高于任何单个circRNA的检测能力(P<0.05)。并且,这组circRNA在两组独立样本(训练集和验证集)中具有类似的检测能力,说明这组circRNA可以作为肺腺癌早期检测的生物标志物。
以上所述,仅为本发明的较佳实施例,并非对本发明任何形式上和实质上的限制,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还将可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。凡熟悉本专业的技术人员,在不脱离本发明的精神和范围的情况下,当可利用以上所揭示的技术内容而做出的些许更动、修饰与演变的等同变化,均为本发明的等效实施例;同时,凡依据本发明的实质技术对上述实施例所作的任何等同变化的更动、修饰与演变,均仍属于本发明的技术方案的范围内。
序列表
<110> 东南大学
<120> 一组用于肺腺癌早期诊断的circRNA标志物及其应用
<130>
<160> 27
<170> PatentIn version 3.3
<210> 1
<211> 816
<212> RNA
<213> Homo sapiens
<400> 1
guagagugga acccccagcu auuagagguc ccaccccaaa cucaguuuga uuacacaguc 60
accaaucuag cugguggucc gaaaccauau ucuccuuacg acucucaaua ccaugagacc 120
acccugaagg ugagcaaugc uuccuugcuc uggggagccc cacugcaaag guuggguugu 180
uuucucuggg cugaguucag caggcuguca gguguuuuca uucuucuuuc ucuuucuucc 240
cuacuuuagg ggggcauguu ugcugggcag cugaccaagg ugggcaugca gcaaauguuu 300
gccuugggag agagacugag gaagaacuau guggaagaca uucccuuucu uucaccaacc 360
uucaacccac aggaggucuu gugagucacu ugaaagggga uguugcacuu aauuuaaggu 420
cuugaacaug aggauaccug uccugacucc ccaagauggu ucccacuguc acccaaggua 480
guuuggggga caacuuguca ugcugcauac ccuuauguca caggaucugg ugaacagguc 540
guuccuggag gucgcauuca uugcacuucg agucucucag gggcugacau cccacagaaa 600
agugaagcau ucuuccuagu uccauagcuc uccuuaugua cucuugaaag accccuggag 660
cguaugugga auaaaauaga guguauauaa uuaaauauuc cuuuuaugag ugucacuauu 720
uucucauuuu uuucaguauu cguuccacua acauuuuucg gaaucuggag uccacccguu 780
guuugcuggc ugggcuuuuc cagugucaga aagaag 816
<210> 2
<211> 15917
<212> RNA
<213> Homo sapiens
<400> 2
gagucggggc ugggccgcgc cgaggcagcu ggcugacucc aguuuagccg ccgccggaga 60
ggacgggcgc cgagccgggg cugcggacuu cggccugccc cucaccucac ucccgcugcu 120
ugcaccuccc ggauggugcu gacugcuccc uaagcggcgg cggcggcgag ucgugaggac 180
gcgccgcgga ggcuguucgg ggucgaggcu ucccgucgcc ggcacuuccu cuugcggcgc 240
ccgugcgcgg ccggcccggc aggcgggaug gcggccgcgg cuccagggaa cggccgcgca 300
ucggcgcccc ggcugcuucu gcucuuucug guuccgcugc ugugggcccc ggcugcgguc 360
cgggccggcc cagaugaaga ccuuagccac cggaacaaag aaccgccggc gccggcccag 420
cagcugcagc cgcagccugu ggcugugcag ggccccgagc cggcccgggu cgaggugagc 480
gggccgggau ggggcgagcg aggcugcagg gccggcugcg ccgaguacca ggcuccaggc 540
cuuugaaagc gccgcacucc gccggccucg gcugggggag gggagcccgg ccccugcucc 600
cgggguggag ggcggucggc ugcgcuguuu uccggugagg ccuggucuug cccgcuccuu 660
uagggaaagg gagagggaga guccaagagg agcccgcuau aaacguugau cuccggaggg 720
ccaagaugcu gcuccgggau gggcguuuua uugaucagau gugucuuaga guagcuagaa 780
agacucaucc cuaccaaaaa guuuuuaaca gaaggcugcu aggaggcuuu uuguauuccc 840
ugaggaucau cacaucggcc auuucauugu ugaaauagcu uaugccaaac ugcuuaccca 900
aauucaacuu ggcacugccu gugcuuuuug ccaaauaugg auuaugaacc augacucuca 960
cuuuuuaaaa augugcuuug gcuagcagga aguagccuuu aggaacgcag aggaauuagu 1020
cuccggcagu acagcgugcu gcagcgaugu gggaugccaa aacuacauuu auaaguaaaa 1080
cagaauccug uauuuugucc uucccugaau agauacuaga aaucaacuuu uuaaucuguu 1140
aauagaauua guccuuaguc acuuggcagc guuuuaacau uucucccuuc ucccagucgu 1200
gggcuuuguc gucauuucca guaucugcuc ccugaauccc ggccagugug gcacucaaac 1260
ccccacuccc acccaggcca cauccagccc aucuccacgu aacuaaucuu cccgaacauu 1320
gaauucugcc aucuugucag aagucgucgg ugaguugccu ccacuaauuu caguccagcc 1380
uuuuuaggag agugauguuc agguuucuuc ugaucuggcu ccagcucacc uccaggcuuu 1440
uuagccaccg cuuucuugcu cauaugcuaa agggauaugc ucaucugcaa aaaagaaugu 1500
gcuucaagag cccuuuggga caggcuuugu gcucucuugc caguuccucc cuaacacaag 1560
accuuuucaa agaaaaaaaa aaaaagaccu ggaguuugaa gccacggauc aacucuuccc 1620
accuuggaga accagcagau accuacucuc ugugaagacu ucccuaaaau uucuugguua 1680
agggugauuu aucugacccu uuccuuuccu uuccuuuccu cuccuuucuc cuuuuuccuu 1740
uccucuccuu ucuccuuuuu ccuuuccauu ccuuucauuu cuccuuuccu uuccuuuuuc 1800
cuuuccuuuc ucccuuccuu uccuuuuucc uuuuucuuug uugagacagg gucucgcucu 1860
gucgcccagg cuggagugca guggccccgu cuuggcucac ugcaaccucu aauugauccu 1920
cccaccucag ccuccugagu ggcugggacu gcaugcgugu gcugacacgc ccggcuaauu 1980
uuuguuuauu uuuuuuuuuu uugagagagg aggucucacu auguugccga gucuagucuc 2040
aaacuccugg gcucaagcgc uucuccggcc uuggccuccc aagugcuggu gagcucucac 2100
accggugcau uguuuucgug uuucauguuu ucguuacaug uuacuuucuu aggcuuuucc 2160
aauuuucugu uguuuuucug uguaagaccg uaggauagaa cuuucugaga gacugaucuu 2220
gguuucacua agcaagaaca uuuguaagaa ucagugcugu cccagaugua guaaucgcua 2280
uugagaaaua augaaguucc ccuuacugga aguacucagg aagaaguuga auaacuaacu 2340
gccuaugagg agauucugau augggaggga aucugggaga uaaaguuacu gggaagugaa 2400
gauucuggga gccgauuuaa uccucacaac agcacguuaa acagguagag gagguuugua 2460
aggaauagug guuuaauauc acagagcuag aagcuaguuu cagcagaacc agaauuagaa 2520
ucuggacuuc ugugccuuac uaaguuuuau uagcauucau ugugucuuac ucuuuugacu 2580
uauuuaauuc acuaauggau uuuaaugguu uauuggauug uaugcuggug caguucuuug 2640
aucuugagcc uagcuuucuc uuucuccuuu uuugggaacu uuauugugua uguuguggca 2700
uguuuacaca cacaucuugc ugccuugggu ucuugcaagu ugugugcgug uuuuaucugc 2760
cccuacuagc uuuuaggugu cuugagagca ugacucuggc uuacucaucu gucuauucca 2820
gaagaccuug ucuguucuug gcauuuauua acuaauuuuc uaagacuggg uugaaguagu 2880
ugcaugucaa guuuauauca gcuguuaaau accuuucugg aaaaacuggc uguaaaauaa 2940
acucaaccag gaaaaaaaaa aaaaaacaac aacccgauuu uuaauagugu cuauccaacc 3000
uuuuuuuuuu aaguugcaag ggauccacca gauggaauua agagaacuaa gcuuuuauca 3060
ucugcuggau auaaugugau uuuguaacca uuauuggauu gguguugguu uagacaguuu 3120
auuuucagcu gacuauauag uuaauuccgg gacucuuaua aaguuuuuuu uaaaaagaga 3180
aaaagagaag aucaaaagca cuggaacuca acgaguaaau aacccauggu aacagagaga 3240
uauaaugcag ugaugucaga gguguacaag aagugugaau cauuuaacau gugaagccag 3300
ggucuuuagu ccacuugggg agagcaaaga ggugaguggg cuucuccauc uuuuuccuuc 3360
ugccugcccu gcuaccccca gccauaugcu uaggaguggg guucccauuu acacugcccu 3420
gcuugucgcu ccuggcucag cugacccugc uugacauguc cacuucagua auugaacuga 3480
aacgcugauu gaugaacuua auucuuagug uucaucuuuu agcccuguca uuuaccccag 3540
uaucacauuu auuuuaaaac aauaacuauu uuggauuaag uuaauugugu gagugagaga 3600
uuaugaauau guaacuuugc agguauuuug uugaaguuuu agucauauug gaauuuuuaa 3660
gauagaaaug augguaggug uagagcuacu aauauccuuu uuaagaagcu aggaaaaauc 3720
uagccaugca gaaugccaca gugguagaaa caguguccag uaaacauauu aaauggucuu 3780
aaggauucuu gucuuuuaaa guuuuauuua auuuuuuuua uagagacaag gucuucuuau 3840
agcucauaac ucauugcagc cuccagcucc uggacucagg ccauccuccu gccucagccu 3900
ucugaguagc ugggaaggga uccuugucuu uaaaacuagg gguauggagg gaaggguggg 3960
uauaauauaa uaugauuuuu ccguuuaaua uuuucauaua uucuugguga uucauuuuag 4020
uuaggcauuu auuuauuauu guuuauucua auuuuguauu auaauagaau auaauugucu 4080
ucuuuucuuc cuuuuuuuuu uuuuuagaga cagggucuca cuauguugcu cagccugccc 4140
ucaaacuccu gggcucaagg gaucuucccc ucuuggccug ccaaaguggu gggauuacag 4200
gcaugagcca ucaugccugg ccuugucuug uuuuuauuuu auauauauaa uauauauaaa 4260
aaauaauaua uaaauauaua auuuauauuu auauuauaua uuaauauauu aauguaauua 4320
auauuauauu auauuaauau auaauauaua auauaauauu auauauuaua uauaauauua 4380
uauauaauau uaauacugua uuauauauaa uauaauauua auuauauuau auuaauauaa 4440
uuaauuauau uaauauaaua auaauaaaua auauuaauau aauuaauaua uuuauauuaa 4500
aauauaaaaa uauaauauau auaauauaua uauauuuuuu ugucucacuc ugucgcccag 4560
gcuggagugc aguggcguga ucuuggcuca cugcaagguc ugccuuccag gcucacgcca 4620
uucuccugcc ucagccucca gcauagcugg gacuacaggc gcccgccacc augcccgccu 4680
aauuuuuugu auuuuuagua gagacgaggu uuuaccgugu uagccaggag gucuccaucu 4740
ccugaccugg ugauccgccu gccucggccu cccaaagugc ugggauuaca ggagugagcc 4800
accacgccug gccuuaauua uauuuuuaug uaacuuuuug auacuacuca aguauuuuuu 4860
ccucuacggu acucacuaug cugaaagauu uuucuuucac auguuuucua aacuauguaa 4920
uauaaguguc auuggcuauu uuuguccacc ugauggaggu aagaaaugau caaaguacag 4980
uuuaacagca guauuagcaa gaguugagcc uugcugaaua uguaaguuuc aacggauuug 5040
cuuugcaacu acaugcagua gauguuuuaa gaggguaggu aggauauuua aauuuaaccu 5100
uuuugugcca cugugugaga gugggcuucu gaaaauggag gggggaagca ucucuccuug 5160
guuaguaggc auucaagugg aagauauguu auaaaaaccu aguuguaucu uauaggaugc 5220
uaaaagcaag gugacugaac uucuaacagg gcauucuaca uugaguaugu gcuuuucucu 5280
auaauuaggc uaaaaaaagg uugguaagua auaugaacuu aaaaucaaga uuaaccccca 5340
auuuacaaac ccaugauaaa aaguguuguu gauuacuugg auccuaucuu uucugcaguu 5400
uauguuucua gugacuuacu caauaguuuu uucuuacucu uucccuggac agaauaugua 5460
auauaagaaa cauaaguccu uugaguugag ggagaucaga uagauuuaau aaaagucauu 5520
uagacuuuau ugcauauucu ggaaguccaa agaagaauga cucugguugc auagcacuuc 5580
uaauaaagcc acaaaaucau uaccugacuc agugccuguu cuuguuauca uauuuuuacu 5640
uuauguuuug guauuucauu uauuuauuac guuucagcug ugagaguacc uucuacaaaa 5700
cauuuuaaac uuuuuucuau uuucauuaag uugcaguccc acuccaccca guccagccuc 5760
cuaauucuag ccuuuauaca gcuaagauug aggcaaucag uuauaaggac gccugcucau 5820
aauuaccuuc ucagaaggua auuauauuaa uacugaauuu auuuaguggu augcugucau 5880
caaaaaaauu cauuaaaaau aaaaucaaug aaggccgggc gcaguggcuc acgcuuguaa 5940
ucccuccacu uugggaggcc gaggugggug gaucaccuga ggucaagagu ucuagaccag 6000
ccuggccaac augaugaaac cccaucucua cugaaaauac aaaaaauuag cugggcgugg 6060
uggcacacac cuguaauccc agcuacucag gaggcugagg caggagaauc gcuugagccc 6120
gggaggugga gguugcagug aaccaagauc gugccacugc ccuccagccu gggcaacaag 6180
agcaaaacuc ugucuccaaa aaaaaaaaag aaacuaaaca cauuuaauaa auuucaagug 6240
cauaaauaca uuacaaaaca acauucauaa aaauaaacau ucauuaaaac aaaaaauaau 6300
uuuauuacaa aauauuacau auaaauucua auauaaauua acaaguaaca auaaaguauu 6360
uaaaaauagu gaaaccauuc acaaaaauac guaaugaaaa uuaaaauacu uuaauguuau 6420
cuuucgaaau cagguuuauc ugugguguca uuguuuaagu gcgugcgugu gugugugugu 6480
guauauauau auauauauau auauauauau auuuuuuuuu uuuuuuuuuu uuuuuuuuuu 6540
uuuuugagac agagucucac ugucacccag gcuggagugc aguggugaga ucuugguuca 6600
cuucaaccuc ugucuccggg guucaugcaa uucucaugcc ucagccucca gaguggcuga 6660
gacuacaggu gcaugccacc acgcccagcu gauuuuugua uuuuuaguag agaugggguu 6720
uugccacguu ggccaggcug gucucaagcu cccaaccucg agugauccac cuaccacgcc 6780
ucccaaguug cuaggauuac aggcaugagc caccaugccc ggccuaagug cauauauauu 6840
uuugggcaca uuuuuacaac uuuuaaaaaa agcuuuuuuu uuuuuuugag acggagucuu 6900
gcucugucgc ccaggcugga gugcaguggc gugaucucgg cucacugcaa gcucugccuc 6960
ccggguucac gccauucucc ugcgucagcc ucccaaguag cugggacuac aggugcccgc 7020
cacacgccca gcuaauuuuu uguauuuuua guagagaugg gguuucacca uguuagccag 7080
gauggucuca aucuccugac cucgugaucc gcccgccugg gccucccaaa gugcugggau 7140
uacaggcaug agccaccaca cccggccccu aaaaaaagcu uuuuugacuu aguagugccc 7200
aggagacagu ucuaagcaaa uuguaagcau uuucuucuga cuccuuuguc uucagauaau 7260
cucaccucuu guuugauaac uuauugagca acuuuguuuc uguuuuuuug cagggacauc 7320
aguuuuuuuc uugguagcaa gcuguagauu uuguuucaag gaaagcaucu ucaucuucuc 7380
uaguuucauc auguauagau ggagauuccg augcagguau cuguaucaau uucaauacag 7440
ucacauuugu guuuauuuga acucuagaac uagaaaagga auuacuuuuu ucuuugauuu 7500
ucuuuuucuu ccuucucuug aggaucauga aaguauaaaa gaauacuuuc uaaaugaggg 7560
ugccuuuuuc uuuuucuuuu uuuuuuuuuu acaauuuuua cauuuggaau uaaaauuuua 7620
acuagaaaag aguuuuuauu aagcaaguuu uuuuaaaaaa aucuuaaguu guuaauccug 7680
cucucaagau guaaguaagg uguguuucag acauuauuaa aauacugaaa uagugguauu 7740
uguaccaaaa cacuaguauc ucauuacuua ccaugauaua uaacacugua uaacugaaua 7800
guggaauacc aaaauugaaa uugcacacug caucuaaucc uguaugcauc caaguauauu 7860
cuucugugcc uguacugucu gccuuuuuca uguuuuggac aaaacuguca uccuuugugu 7920
accuccucuc uguguccacg uuccuauucu ccucccucag ugccuuuauu cucucccuuc 7980
ccauugcuuc cuuuguaucu gcuuacacau guucauaugu uucucuuauu uuggaaaaga 8040
aagaaaaagg ucauucauuu aaucuuaacu ugacuauuag uuucguuuuc uuuccuuccu 8100
uccuuccuuc cuucuuucuu uccuuuuuuu uuuuuuuuuu gacagugucu ugcucuguug 8160
cccagccugg agugcagugg gcacaaucuu ggcacacugc aaccucagcc uuccgagugg 8220
cuaggacuac aggugugcgc caccacgccu ggcuauuuuu uuuuuuugua cuuuuaguag 8280
agaugggguu ucaucauguu ugccaggcag cucuugaauu ccugaccuca gaucugucca 8340
ccucggccuc ccaaagugcu gggaugacag gcgugagcca ccaugcccag ccauauuagu 8400
uucuucaguu uuauaaacca aacuucuaac uaggggauuu gcugcuuuuu cacuuuacuu 8460
uaguauguug uuaucuggcu ucaguccuug ccuuuuccuu gaaauucuuu uuuuaauuuu 8520
aaagauaggg ucuugcucug ucgcccuggc uggaguucag uggcacaauc auagcuuacu 8580
gcagccugga acuagugggc ucaagugauc cucccaccuc agccucccaa guagcuggga 8640
cuacaggugc augccaccac accuggcuaa uuuuauuuau uuuauuuuuu uuuuuugugg 8700
agaugagguc ucacuauguu gcccaggcug gccucgaacu cuuggccuca agcaguccuc 8760
cugcaucggc cucccaaagu gcugggauua uaggcaugag ccaccacaaa uuccauuuuu 8820
ugaaagaauc uuguaaguua gcaaauugcu aaauccaggg aucuuuuuca guucucauuu 8880
gacacuguua auucucuacu guuuaagaau ccaucucagg uguaugaacu uggcagaaua 8940
augaagcccg uuugaccuca guuuuccugu auuaaaacuu aaaacagcuc cuaaguuuuu 9000
uugaguauca aaugcaacaa ugugucugaa aauaucucgc aucuaguuag uagcgcaccc 9060
caaccugacg gucugugaug cuuuaguugc ugccuggcuc gaaauaucua agauaguuuu 9120
uuuuccuauu uuuuuuccuc ccuccaccuu cuuugaauaa agacauucuc uaaggcgcau 9180
ucuuugaacu uuaucucuuu gccuuaucug uuggaaaucu caucuacuug cagagcuuua 9240
gcugauaaau uugggcugcc agcaaccaga uagaguacgu ccucacuuaa uguuauuaau 9300
agauucuugg aaauggucac uuuaagugaa augacaucaa ugaugucauu uuaauucagu 9360
guuguuucau uauaacauug augagaaaag aaaguugguu uucuuuuaca ucauuucacu 9420
uaaaguugca guuuccaaga gccuauugag gacacgaagg cugucaaccu ugaggcuaca 9480
uaccuugagg cuguccuagg cuaaacucug gugauccauu ucugauaacc ucuuucaaac 9540
cuucauuuga aaugcuuuuu aucaccccaa guggaaugua uaugaaacca aaccccuugu 9600
uuuuauuccc cuuuccgaca uaccuuuuaa gaguacuaaa uacauaauag cguuuuaaga 9660
guacuaauau uucugccaac cagaaaaccu caccaccauc uuugauuccc cccaucccgc 9720
cuaccuuuuu uuaaaggucu agugauuuuu cuuuccauug ugugcagaau uuuuuccuuc 9780
ucuuauuugu cuuaacacgg guuucaugca gcugaccucc ugauugaucc aguggcugau 9840
acuccccacu cugcccugau aauuggucac agugccuuga ugguguuuau guguuacaca 9900
aaaauaugua augacuuccc ucuugccucu gagcuugucc acaaacauaa agaauuucag 9960
gcccaguuua ucuuucucau cuugccccaa ccauucuucu gaugguuuac uucuuguucu 10020
cagaacaugc cuauauucuu ucacauuguc aguacagaaa agagguauau gcagaaaagg 10080
agugauguau uuucaaguua gccacuccau gagugacuag uacugaaucc cacugaaauc 10140
ccacugaaac uucccaggag gcuuaugaaa ugaaucuuag aaccagcuuc cauauuggua 10200
gcccuacagc uauuaacuuc ccauacuucc agguagugaa ugaguaaaua cagagcagug 10260
cuuuuugguu ggaccugccu gaagucaguc acagcuuaca agaaauugau ccuccauagc 10320
uggcauaaga uguuggguca ggaaguuuuu gaaaugguac auagcaugug ucuauaaugg 10380
ugugaaaguu aaaaauucca gaagauacag aagaauguag aaugagaagu uacgucucuu 10440
uuccuuuuuu guauucuaga aaaaguuugc caaccccugu ucuagucauu cugguuccuu 10500
uccuggaaac auucaucauu aaccuguuuc uugagacgug guguguauuu augauacuua 10560
caccauccac auguacacau acuuaguaua uacuuuuucu caacuucaaa auaucuuaau 10620
gauuuucuau auuaguguau agaacauucu uauuauucuu uuagcucuau aauauuccgu 10680
uauguggauc uaccauuuau uuaacuaguu uucuaucaau ggacauuuag uuguuuuuuu 10740
cuuucucuuu guuuugagac agggucucac ucuguugccc aggcuggagu gcagugaugu 10800
caucucugcu cacugcaacu uguaccuccu gggcucaagc gauccucuca ccucacagcc 10860
ucccaaauag cuggaaacua caggugugug ccaccacacc cagcuacuuu uguauuuuuu 10920
guagagacag ggucucacuu uguugcccag gcuggucuug aacuccuggg cucaagggcu 10980
ccacccaucu cccaaagugc ugggauuaca ggcaugagcc acugagccca gccgacauuu 11040
aguuauuuug ucucuuuauu acaaaugaua gcauuacauu uauacauauu uguaauccga 11100
aaaggucaau uccuugagug uuucugucuu gaacuuuuuu cuguaauagg ccucccauac 11160
ucauugccca caguuugcau ucaguuuuau uguagugggu caggaucauu aagagcugga 11220
guugcuggga uaggccuuuc ucaagagguu cuacuugagu uggaccuuga ggaaucugga 11280
ugaagagggg gauaacgaaa aggagguggg aagggaaaaa ggacugugug gcugaaggcu 11340
ugugguuagc aaaagccugu caugcuuucg agcugcacug cccagcacug uaaccaugag 11400
ccaugaguau guguggcugu gagcacuuga uauguggcua auccagaguu gaggugugcg 11460
gugaguaaau accuaccagg gucugaagau uuaauaugaa aaaaagaaug uuaaaauauc 11520
ucaguaguuu uaaaaauauu gcuuauaauu uaaauaguag cauuuuggau auauuggguu 11580
aaguaaaaug uuauuaaaau uuuuaccugg uuuuacuuuu aaauauaugg cuaccagaaa 11640
auguaaaauu guauuaugug gccuaccuuu guggcugcau gauuuuuugu uagacucugc 11700
ucuggcucau ccuucaggau ggagaagcag guucauuugg ggaaccuggu augugcuuca 11760
gugagaacug uuggauaguu accagaauca aguauuuggu augaaaagac cauuacguuu 11820
cuuaaaacag ugaaguaaca ugaaauuagu uucaggaaga uucaacuguu cauauuuugu 11880
ggcacuacaa aaacuaauug agcacuuacu guguacugag cacuguccua aagggcuuua 11940
uucauuuaau ccucacagca acccuuugag acauagguag cccuuauguu acagaugaac 12000
uugagucaca ggggggugua ccuauuggcc caaggucacg ccguaacuga uaaugccuug 12060
gcuaugaacu ggcagucuga uuccagagcc uauacacuua accacuacac ugugucccug 12120
ugaaggugaa uuagacaaag aagaugaucc uugcacauag cagugaagga augguaaugg 12180
aucacuuuuu aauccuguua auauuuuaau uaaaaaagau cuucuaucuu cacgguaccc 12240
cgauacuuuu cguuuuaagu ucuugucacc augauugguu guaugauuuu ggccacccag 12300
gaccagcuua guauguaaca agcuuuaugu uuauuuuucu uguguuuugu guguaggaag 12360
guuuuaagaa uauguagcau cgcuuaauga uggggaugug uucugagaaa cucauuauca 12420
ggcaauuuca uugugcagac guccuagagu guacucaaca caaaccuaga uguauaaccu 12480
gcuauacacc uaggcuaaau gguauagccu auggcuuuua ggcuacaaau cuguacagcg 12540
uguuacuaua uuaaauacug uaggcaguug uaacauuuua uauauauaaa aaaacauaga 12600
aaagguaaag uaaaaaauuu gguacuguaa ucuuauggga cuacugcugc auauucggcc 12660
caucauugau caaauuguca ucauguggug caugucugua cucuuaaagc aaauuuuauu 12720
uuaucccuac auuuuacaga ggaacagaga uuaaauaaug uggcugaagu uucauggcug 12780
ggaauuauaa aaccaugaga cuguguagcu uugaucacua uuguguuuga uuuaaaaagu 12840
aaacauuuug uguuugagcu uagagcuaag ugaucauaaa ugguguauau uuauuccuaa 12900
aauuuuucug ggauuucaga uccugaaauu uuauacaaac cuuuaaaaag cauuuucagg 12960
aggaaaaugu gucagagcca aguugaaauu ugaaaugccc uuuuuuuuuu uuuuaauaua 13020
aggauucuua auauuggaag agaaaggaag uuguuguuuu gagaaggggg cuugcuccau 13080
cacccaggcu ggagugcaau ggugccauua cagcucacug caggaagcuc guuuuuaaag 13140
gaccgucaac guagguggaa ccaaaauaau ggagagaaag caagaagccc uuaaaaugau 13200
acuugcuuaa uuaauuaaac ucaauucauu gagagccagc ugucaaggca acaaauacuu 13260
uccauuuugu uaaauuucuc caguauuuag cucagagguc uagucuuaau gguaaugccu 13320
aaauuuuucu gaucuuuacu guggaauuuu auaaucuuua uguuaugugu uaaggaauga 13380
caugcacacu aagaauuuau gauuuuauuc uuaccuguga cuagggccuu uguaauaaau 13440
cuguuuuuac gcuguccaaa auuacuaugu ucuuggguuu cuuuuucuuu aucucuuggg 13500
uuucuagaga uucauaagcu uaaaaaauua aaaauaaguu auuaggauug gaagagaccu 13560
uuggaagugg uuuaucuagc ccagggcguc ucagucuggg aacuguugac auuuuggaua 13620
uauaauucuu gguuguggaa gggcuguccu gugcauugua ggauguuuag cagcguuucu 13680
ggccucuacc cacuagaugc caguaguucc ccuuugauug uaacuaaaaa uguccgcaag 13740
cauugucaga uguccccugg gagacaaaau cgcccugguu gagaaccgcu ugucuagccc 13800
auuuccuggg aguggugguu cccuucucug gaacucagac guugagaaga gaaggguauu 13860
uaccaccucc ucuagcaguc uguuccaacu uugggugcgu cuuuggagac agaaaucucu 13920
ccucucuguu aagcuaaaac cugccaucuc uaacuuuuua guucugccuc uuaggaccgu 13980
auggauugga uagauucacu uaaaaacuuu cccaauuauu ggaacaugau accccguccu 14040
uccugguccc ucacgggauu guuuuagagc caagucagca aacuucuugu aguugccaug 14100
uauuugcagg cuaccaaucu cugaugcaua aucuuccuuu ccuucccucc cuccuccuug 14160
ccucccacca gccuucccuc cuuuucucuu ucuucuuauu ucuuguaacu ucuuaaaaau 14220
guaaaaaacc uuuuuuugcu cuuauaggcu ggguuuuggu ucaguaacuu gccaucccug 14280
guuuuagagu cugacaucug cuaaucuuca gagggcagug cagugcuuua gaacuguaua 14340
uagaacuuug gggaaggucu gagcagcaua gaauaacguu ggacuuguca uuaacuccuu 14400
caugcgaaga gcuuacugcu uuuuugaagc uuugucacau uuacagcgua augacagcca 14460
agacacuggu uugucuuuuu cauuaggcca cuuuaccuuc uuuuuuuuug agacagaguu 14520
ucacucauug cccauugugc aaugggcgca gucucagcuc acugcaaccu ccgccuccca 14580
gguugaagca auucucccgu cucagccucc caaguaacug ggauuauagg cuuccgccac 14640
caugccacuu uaccuucuaa gauauuuuua gacuucagcg uaggacgauc uguguuaaca 14700
gcuguauuaa acuugucuua gcuggaacca acucucuaua cccugcugag guuugugggu 14760
cuuacucugu ccuucagagu guuaaugaaa uuuuucuuag cuucccgucg uucaaauguu 14820
uuuuaaacau accugggucu uucaugcaag uuacuaauac aaauuugaau gagauguagc 14880
uaagaacuaa aucugaaauc acaaaugccu aacaaauaag guaauuuugg ccaagcgugg 14940
uggcucacgc cuguaaucuc agcacuuugg gaggcugagg uggguggauc acuugagguc 15000
aggaguuuga gaccagccug gccaacauga ugagaaaccc ugucuugacu aaaaauacaa 15060
aaauuagcug ggcuuggugg ugcauaccua uaaucccagc uacuugugag gcugaggcag 15120
gagaaucgcu ugaaccuggg agguggaggu ugcagugagc caagaucaca ccacugcacu 15180
ccagccugag ugacagagug agauuuuguc ucaaaaaaaa aaaaaaaaag ggaauuuuaa 15240
ugcauggaua uagcaggucu guacucuguu cuuaaaauug uuuuggagaa uuauauguaa 15300
aucugcauua uacauguuua guauccucaa ucuaaaaucc acagugcucc aaaaucugaa 15360
acuugagcac ugacauacau gaaaugcuca auggaacauu uuggauuucu ggauuagggg 15420
uacucagcua ugauauaaau auuccaaaau cuaaaaaaau ccaaaauucc aacuacuucu 15480
ggucccauac auuucaggua agggauacuc aaauuguagc aaccaucguc agagguuacc 15540
gucguuacug auggcuuuca gagugauuag acaguaaaua aguguaauga ccaugacaag 15600
aaaauuuuca aaaaaacuaa aucuuauuua cgugcaaaau aaaauaauuu ugaauaauga 15660
uuuuaagaag uaacugauuu uuuuuuucca gaaaauauuu acaccagcag cuccaguuca 15720
uaccaauaaa gaagauccug cuacccaaac uaauuuggga uuuauccaug cauuugucgc 15780
ugccauauca guuauuauug uaucugaauu gggugauaag acauuuuuua uagcagccau 15840
cauggcaaug cgcuauaacc gccugaccgu gcuggcuggu gcaaugcuug ccuugggacu 15900
aaugacaugc uugucag 15917
<210> 3
<211> 239
<212> RNA
<213> Homo sapiens
<400> 3
gaucagcauu gaggcccgca agucacccaa gcugccccgg gcugcucagg agcucucccg 60
guccccacgg uugccccugc gcaagcccuc ugugggcucg cccagccuga cucggagaga 120
guuuccuuuu gaagacauca cucagcacaa cuaucuugcu caggucacgu cuaauaucug 180
gggaaccaaa uuuaagauug ugggcuuggc ugcuuuccug ccaaccaacc ucggugcag 239
<210> 4
<211> 389
<212> RNA
<213> Homo sapiens
<400> 4
gcaauuuuua cccagaaaag caagccgggg ccugacccgu uggacacgag acgcuugcag 60
ggcuuucggc uggaggagua ucugauaggg caguccauug guaagggcug cagugcugcu 120
guguaugaag ccaccaugcc uacauugccc cagaaccugg aggugacaaa gagcaccggg 180
uugcuuccag ggagaggccc agguaccagu gcaccaggag aagggcagga gcgagcuccg 240
ggggccccug ccuuccccuu ggccaucaag augaugugga acaucucggc agguuccucc 300
agcgaagcca ucuugaacac aaugagccag gagcuggucc cagcgagccg aguggccuug 360
gcuggggagu auggagcagu cacuuacag 389
<210> 5
<211> 471
<212> RNA
<213> Homo sapiens
<400> 5
agggguguuu gaugcuuccc ucaaaauggc uggcuucuau ggauuguaua ccuggcugac 60
ucauacuaug uuuggcauca auauugucuu cauaccauca gcauuagcag caauccuugg 120
agcagugcca uuccugggga cauacugggc agcaguaccu gcaguucuug accuguggcu 180
gacacaaggg uuaggaugca aggccauuuu acuguugauu uuucaucucu ugccaacaua 240
cuuuguagau acugcaaucu acucugacau aucaggaggu ggccauccuu accugacagg 300
cuuggcagug gccgguggag cauacuaccu aggccuggaa ggagcaauca ucgguccuau 360
ucuucucugc auacuugugg uugcuuccaa uaucuauagu gccaugcuag ugagucccac 420
gaauucaguu cccacgccaa accagacccc auggccugcu cagccucagc g 471
<210> 6
<211> 359
<212> RNA
<213> Homo sapiens
<400> 6
guacuuuaau uaucggacua ccagguuccu ggcugaggag ggguuuuaua aauuccauaa 60
cugguuugau gaccgagccu gguacccuuu gggacgaauc auuggaggaa caauuuaccc 120
agguuuaaug aucaccucug cugcaaucua ccauguacuc cauuuuuucc acaucaccau 180
cgacauucgg aaugucugug uguuccuggc cccucucuuc uccuccuuca ccaccaucgu 240
cacguaccac cuuaccaaag agcucaagga ugcaggggcu gggcuucuug cugcugccau 300
gauugcugua guuccuggau auaucucccg aucuguggcu ggcuccuaug auaaugaag 359
<210> 7
<211> 146
<212> RNA
<213> Homo sapiens
<400> 7
uggcuggcgu ggcucaccga uuccacagua cuugcggcaa gaacgucacu cuagaggagg 60
auggcacgag ggcagugcgu gccgcuggcu augcucaugg ccuugucuuc aguaccaagg 120
agcugagggc ugaggaaguc uuugag 146
<210> 8
<211> 266
<212> RNA
<213> Homo sapiens
<400> 8
cuuggcuugu ggagauguug aaggaaaguu ugauauuuua uucaauagag uucaagcaau 60
ucagaagaaa aguggaaacu uugaucugcu guugugugua ggaaauuucu uuggcuccac 120
ccaagaugcu gaaugggagg aguauaagac uggcaucaag aaagcuccua uucagacaua 180
ugugcuuggu gcuaauaacc aggaaacagu aaaauauuuc caggaugcug auggauguga 240
auuagcugaa aacauuacuu aucugg 266
<210> 9
<211> 21
<212> DNA
<213> 人工序列
<400> 9
gtttgctggc tgggcttttc c 21
<210> 10
<211> 24
<212> DNA
<213> 人工序列
<400> 10
gggacctcta atagctgggg gttc 24
<210> 11
<211> 23
<212> DNA
<213> 人工序列
<400> 11
tgcttgcctt gggactaatg aca 23
<210> 12
<211> 20
<212> DNA
<213> 人工序列
<400> 12
cggcggctaa actggagtca 20
<210> 13
<211> 23
<212> DNA
<213> 人工序列
<400> 13
tttaagattg tgggcttggc tgc 23
<210> 14
<211> 17
<212> DNA
<213> 人工序列
<400> 14
gcgggcctca atgctga 17
<210> 15
<211> 20
<212> DNA
<213> 人工序列
<400> 15
gtggccttgg ctggggagta 20
<210> 16
<211> 23
<212> DNA
<213> 人工序列
<400> 16
ccggcttgct tttctgggta aaa 23
<210> 17
<211> 20
<212> DNA
<213> 人工序列
<400> 17
acgccaaacc agaccccatg 20
<210> 18
<211> 22
<212> DNA
<213> 人工序列
<400> 18
agccagccat tttgagggaa gc 22
<210> 19
<211> 24
<212> DNA
<213> 人工序列
<400> 19
tgtggctggc tcctatgata atga 24
<210> 20
<211> 25
<212> DNA
<213> 人工序列
<400> 20
atttataaaa cccctcctca gccag 25
<210> 21
<211> 24
<212> DNA
<213> 人工序列
<400> 21
ctgagggctg aggaagtctt tgag 24
<210> 22
<211> 20
<212> DNA
<213> 人工序列
<400> 22
agagtgacgt tcttgccgca 20
<210> 23
<211> 24
<212> DNA
<213> 人工序列
<400> 23
tgtggctggc tcctatgata atga 24
<210> 24
<211> 25
<212> DNA
<213> 人工序列
<400> 24
atttataaaa cccctcctca gccag 25
<210> 25
<211> 20
<212> DNA
<213> 人工序列
<400> 25
ttcttttgcg tcgccagccg 20
<210> 26
<211> 20
<212> DNA
<213> 人工序列
<400> 26
ggtgaccagg cgcccaatac 20
<210> 27
<211> 1455
<212> RNA
<213> Homo sapiens
<400> 27
ggcaccgcag gccccgggau gcuagugcgc agcgggugca ucccuguccg gaugcugcgc 60
cugcgguaga gcggccgcca uguugcaacc gggaaggaaa ugaaugggca gccguuagga 120
aagccugccg gugacuaacc cugcgcuccu gccucgaugg guggagucgc guguggcggg 180
gaagucaggu ggagcgaggc uagcuggccc gauuucuccu ccgggugaug cuuuuccuag 240
auuauucucu gauuuggucg uauugggcgc cuggucacca gggcugcuuu uaacucuggu 300
aaaguggaua uuguugccau caaugacccc uucauugacc ucaacuacau gguuuacaug 360
uuccaauaug auuccaccca uggcaaauuc cauggcaccg ucaaggcuga gaacgggaag 420
cuugucauca auggaaaucc caucaccauc uuccaggagc gagaucccuc caaaaucaag 480
uggggcgaug cuggcgcuga guacgucgug gaguccacug gcgucuucac caccauggag 540
aaggcugggg cucauuugca ggggggagcc aaaaggguca ucaucucugc ccccucugcu 600
gaugccccca uguucgucau gggugugaac caugagaagu augacaacag ccucaagauc 660
aucagcaaug ccuccugcac caccaacugc uuagcacccc uggccaaggu cauccaugac 720
aacuuuggua ucguggaagg acucaugacc acaguccaug ccaucacugc cacccagaag 780
acuguggaug gccccuccgg gaaacugugg cgugauggcc gcggggcucu ccagaacauc 840
aucccugccu cuacuggcgc ugccaaggcu gugggcaagg ucaucccuga gcugaacggg 900
aagcucacug gcauggccuu ccgugucccc acugccaacg ugucaguggu ggaccugacc 960
ugccgucuag aaaaaccugc caaauaugau gacaucaaga agguggugaa gcaggcgucg 1020
gagggccccc ucaagggcau ccugggcuac acugagcacc agguggucuc cucugacuuc 1080
aacagcgaca cccacuccuc caccuuugac gcuggggcug gcauugcccu caacgaccac 1140
uuugucaagc ucauuuccug guaugacaac gaauuuggcu acagcaacag ggugguggac 1200
cucauggccc acauggccuc caaggaguaa gaccccugga ccaccagccc cagcaagagc 1260
acaagaggaa gagagagacc cucacugcug gggagucccu gccacacuca gucccccacc 1320
acacugaauc uccccuccuc acaguugcca uguagacccc uugaagaggg gaggggccua 1380
gggagccgca ccuugucaug uaccaucaau aaaguacccu gugcucaacc aguuaaaaaa 1440
aaaaaaaaaa aaaaa 1455
Claims (9)
1.一组用于肺腺癌早期诊断的circRNA标志物,其特征在于所示的标志物包括:SEQ IDNo:1 所示的circRNA_100323、SEQ ID No:2 所示的circRNA_69774、SEQ ID No:3 所示的circRNA_403738、SEQ ID No:4 所示的circRNA_ 404449四种circRNA。
2.如权利要求1 所述一组用于肺腺癌早期诊断的circRNA标志物,其特征在于所述肺腺癌为人早期肺腺癌。
3.权利要求1所述circRNA标志物的引物组合,其特征在于所述circRNA 引物的组合包括:针对circRNA_100323的特异性引物、针对circRNA_69774的特异性引物、针对circRNA_403738的特异性引物、针对circRNA_ 404449的特异性引物。
4.如权利要求3所述circRNA标志物的引物组合,其特征在于所述针对circRNA_100323的特异性引物包括如SEQ ID No:9 所示的上游引物,如SEQ IDNo:10 所示的下游引物;所述针对circRNA_69774的特异性引物包括如SEQ ID No:11所示的上游引物,如SEQ ID No:12 所示的下游引物;所述针对circRNA_403738的特异性引物包括如SEQ ID No:13 所示的上游引物,如SEQ ID No:14 所示的下游引物;所述针对circRNA_ 404449的特异性引物包括如SEQ ID No:15所示的上游引物,如SEQ ID No:16所示的下游引物。
5.如权利要求3 所述circRNA标志物的引物组合,其特征在于所述circRNA引物的组合还包括:针对SEQ ID No:5 所示的circRNA_104855的特异性引物、针对SEQ ID No:6所示的circRNA_100983的特异性引物、针对SEQ ID No:7 所示的circRNA_1011969的特异性引物、针对SEQ ID No:8 所示的circRNA_006718的特异性引物。
6.如权利要求5 所述circRNA标志物的引物组合,其特征在于所述针对circRNA_104855的特异性引物包括:如SEQ ID No:17 所示的上游引物和如SEQ IDNo:18 所示的下游引物;所述针对circRNA_100983的特异性引物包括:如SEQ ID No:19 所示的上游引物和如SEQ IDNo:20 所示的下游引物;所述针对circRNA_1011969的特异性引物包括:如SEQ IDNo:21 所示的上游引物和如SEQ IDNo:22 所示的下游引物;所述针对circRNA_006718的特异性引物包括:如SEQ ID No:23 所示的上游引物和如SEQ IDNo:24 所示的下游引物。
7.权利要求3-5任一权利要求所述的circRNA标志物的引物组合在制备或筛选人肺腺癌的肿瘤诊断药物中的用途。
8.一种人肺腺癌的肿瘤诊断试剂盒,其特征在于包括如权利要求3-5任一权利要求所述的circRNA 标志物的引物组合。
9.一种检测人肺腺癌的circRNA 芯片,其特征在于所述circRNA 芯片包括固相载体以及固定于固相载体上的针对如权利要求1所述的circRNA 生物标志物的探针。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610876817.4A CN106434928B (zh) | 2016-10-08 | 2016-10-08 | 一组用于肺腺癌早期诊断的circRNA标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610876817.4A CN106434928B (zh) | 2016-10-08 | 2016-10-08 | 一组用于肺腺癌早期诊断的circRNA标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106434928A true CN106434928A (zh) | 2017-02-22 |
CN106434928B CN106434928B (zh) | 2019-12-31 |
Family
ID=58173234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610876817.4A Active CN106434928B (zh) | 2016-10-08 | 2016-10-08 | 一组用于肺腺癌早期诊断的circRNA标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106434928B (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107488724A (zh) * | 2017-09-21 | 2017-12-19 | 顾万君 | 用于活动性肺结核无创诊断的外周血环状rna标记物及应用 |
CN107557473A (zh) * | 2017-10-27 | 2018-01-09 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ6:79060478|79060818及应用 |
CN107586848A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤预后标志物circ8:127890589|127890998及应用 |
CN107586843A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ7:100812747|100813208及应用 |
CN107586849A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 脑组织来源的circ9:4117768|4118881的应用 |
CN107586846A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ3:129880309|129880559及应用 |
CN107586844A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤预后标志物Circ9:135881633|135883078的应用 |
CN107586845A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ19:5604583|5604936及应用 |
CN107604076A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ6:4891713|4892379及应用 |
CN107604073A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ22:42890947|42891182及应用 |
CN107604072A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ15:98707562|98708107的应用 |
CN107604070A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ9:4117768|4118881及应用 |
CN107604075A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ7:66286511|66286709及应用 |
CN107604071A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ19:5604583|5604936的应用 |
CN107641654A (zh) * | 2017-10-27 | 2018-01-30 | 中南大学湘雅医院 | 胶质瘤预后标志物circ11:66639700|66640123及应用 |
CN108866193A (zh) * | 2018-08-09 | 2018-11-23 | 四川大学华西第二医院 | 一种染料法数字定量pcr试剂盒及其应用和使用方法 |
CN108977513A (zh) * | 2018-08-09 | 2018-12-11 | 四川大学华西第二医院 | 一种探针法数字定量pcr试剂盒及其应用和使用方法 |
CN109439747A (zh) * | 2018-09-17 | 2019-03-08 | 昆明医科大学第附属医院 | 一组用于肺癌诊断的circRNA标志物及其应用 |
CN109609636A (zh) * | 2018-12-29 | 2019-04-12 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
CN110373485A (zh) * | 2019-07-30 | 2019-10-25 | 中山大学达安基因股份有限公司 | 一种解脲脲原体、沙眼衣原体和淋球菌三联检试剂盒 |
CN113304267A (zh) * | 2021-06-11 | 2021-08-27 | 河南大学 | 肺癌的治疗靶点及其应用 |
CN116144772A (zh) * | 2022-11-18 | 2023-05-23 | 昆明医科大学第一附属医院 | 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105018638A (zh) * | 2015-08-25 | 2015-11-04 | 王振宁 | 胃癌发生相关分子标志物lncRNA HOTTIP的检测及应用 |
WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
-
2016
- 2016-10-08 CN CN201610876817.4A patent/CN106434928B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
CN105018638A (zh) * | 2015-08-25 | 2015-11-04 | 王振宁 | 胃癌发生相关分子标志物lncRNA HOTTIP的检测及应用 |
Non-Patent Citations (1)
Title |
---|
陈明达: "肺腺癌CircRNA芯片筛选及其调控机制探讨", 《中国学术文献网络出版总库》 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107488724A (zh) * | 2017-09-21 | 2017-12-19 | 顾万君 | 用于活动性肺结核无创诊断的外周血环状rna标记物及应用 |
CN107604075A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ7:66286511|66286709及应用 |
CN107586843A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ7:100812747|100813208及应用 |
CN107641654A (zh) * | 2017-10-27 | 2018-01-30 | 中南大学湘雅医院 | 胶质瘤预后标志物circ11:66639700|66640123及应用 |
CN107604071A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ19:5604583|5604936的应用 |
CN107586846A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ3:129880309|129880559及应用 |
CN107586844A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤预后标志物Circ9:135881633|135883078的应用 |
CN107586845A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ19:5604583|5604936及应用 |
CN107604076A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物Circ6:4891713|4892379及应用 |
CN107604073A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ22:42890947|42891182及应用 |
CN107604072A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤预后标志物circ15:98707562|98708107的应用 |
CN107604070A (zh) * | 2017-10-27 | 2018-01-19 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ9:4117768|4118881及应用 |
CN107557473A (zh) * | 2017-10-27 | 2018-01-09 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ6:79060478|79060818及应用 |
CN107586849A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 脑组织来源的circ9:4117768|4118881的应用 |
CN107586848A (zh) * | 2017-10-27 | 2018-01-16 | 中南大学湘雅医院 | 胶质瘤预后标志物circ8:127890589|127890998及应用 |
CN108977513A (zh) * | 2018-08-09 | 2018-12-11 | 四川大学华西第二医院 | 一种探针法数字定量pcr试剂盒及其应用和使用方法 |
CN108977513B (zh) * | 2018-08-09 | 2021-10-22 | 四川大学华西第二医院 | 一种探针法数字定量pcr试剂盒及其应用和使用方法 |
CN108866193A (zh) * | 2018-08-09 | 2018-11-23 | 四川大学华西第二医院 | 一种染料法数字定量pcr试剂盒及其应用和使用方法 |
CN109439747A (zh) * | 2018-09-17 | 2019-03-08 | 昆明医科大学第附属医院 | 一组用于肺癌诊断的circRNA标志物及其应用 |
CN109439747B (zh) * | 2018-09-17 | 2021-07-30 | 昆明医科大学第一附属医院 | 一组用于肺癌诊断的circRNA标志物及其应用 |
CN109609636A (zh) * | 2018-12-29 | 2019-04-12 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
CN109609636B (zh) * | 2018-12-29 | 2021-11-30 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
CN110373485A (zh) * | 2019-07-30 | 2019-10-25 | 中山大学达安基因股份有限公司 | 一种解脲脲原体、沙眼衣原体和淋球菌三联检试剂盒 |
CN113304267A (zh) * | 2021-06-11 | 2021-08-27 | 河南大学 | 肺癌的治疗靶点及其应用 |
CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
CN116144772B (zh) * | 2022-11-18 | 2023-08-25 | 昆明医科大学第一附属医院 | 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用 |
CN116144772A (zh) * | 2022-11-18 | 2023-05-23 | 昆明医科大学第一附属医院 | 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106434928B (zh) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106434928A (zh) | 一组用于肺腺癌早期诊断的circRNA标志物及其应用 | |
CN101608241B (zh) | 用于检测人类K-ras基因突变的引物、探针及其试剂盒 | |
CN108949990B (zh) | 一种检测egfr基因突变的试剂盒及方法 | |
CN109439749A (zh) | 用于结直肠癌诊断的外泌体miRNA标志物及诊断试剂盒 | |
CN105483218A (zh) | 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 | |
CN108085395A (zh) | 基于高通量测序的宫颈癌多基因甲基化检测的引物组、试剂盒及方法 | |
CN109504778A (zh) | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 | |
CN106350589A (zh) | 一种检测遗传性血管疾病致病基因的dna文库及其应用 | |
CN107177683B (zh) | 一种膀胱癌筛选检测试剂盒 | |
CN114438214A (zh) | 结直肠癌肿瘤标志物及其检测方法与装置 | |
CN109234394A (zh) | 一种肝癌诊断标志物及其筛选方法 | |
CN104818322B (zh) | miRNA和Cyfra21‑1联合在检测非小细胞肺癌中的应用 | |
CN105624166B (zh) | 一种检测人膀胱移行细胞癌细胞的核酸适配体及其在制备检测制剂中的应用 | |
CN112553344B (zh) | 一种与结直肠癌相关的生物标志物及其应用 | |
CN107475389A (zh) | 用于检测肺炎支原体的引物组、试剂盒及方法 | |
CN110229910A (zh) | Myd88基因l265p突变检测试剂盒及检测方法 | |
WO2024120090A1 (en) | Kit for detecting nucleic acid of helicobacter pylori in human feces | |
CN109790586A (zh) | 诊断和治疗醋酸阿比特龙-糖皮质激素抵抗型或敏感型转移性去势抵抗性前列腺癌的方法 | |
CN107604069A (zh) | 基于Taqman‑MGB探针的人JAK2 V617F突变检测试剂盒和方法 | |
CN109295225A (zh) | Egfr基因l858r突变数字pcr检测体系的优化方法及检测产品 | |
CN105838779A (zh) | ddPCR技术监控胃肠道间质瘤患者对伊马替尼/舒尼替尼耐药的方法 | |
CN104962612B (zh) | BRCA1基因g.41256139delT移码突变及其在制备乳腺癌辅助诊断试剂盒中的应用 | |
Tadiotto Cicogna et al. | Diagnostic Workup of Primary Cutaneous B Cell Lymphomas: A Clinician's Approach | |
CN101671728B (zh) | 一种检测癌胚抗原mRNA表达量的方法及专用试剂盒 | |
CN109880903A (zh) | 一种用于非小细胞肺癌辅助诊断的snp标志物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |